A Case of Fulminant Type 1 Diabetes Mellitus, Secondary Adrenal Insufficiency, and Hypothyroidism after Pembrolizumab Administration

DOI
  • Tanaka Hajime
    Division of Diabetes & Endocrinology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Tanaka Shinichi
    Division of Diabetes & Endocrinology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Sonoda Kenji
    Division of Diabetes & Endocrinology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Hoshino Mai
    Division of Medical Oncology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Sakai Gen
    Division of Medical Oncology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Katsuki Takeshi
    Division of Diabetes & Endocrinology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Funakoshi Shinsuke
    Division of Medical Oncology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital
  • Kawai Toshihide
    Division of Diabetes & Endocrinology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital

Bibliographic Information

Other Title
  • ペムブロリズマブ投与後に劇症1型糖尿病，続発性副腎皮質機能低下症，甲状腺機能低下症を発症した1例

Search this article

Abstract

<p>After starting the immune checkpoint inhibitor pembrolizumab in October X-1 for postoperative recurrence of transverse colon cancer, a 77-year-old man with no history of diabetes mellitus visited our hospital in January X with complaints of general fatigue, decreased appetite, thirst, and heavy drinking. He was urgently admitted to the hospital with diabetic ketosis: random blood glucose 341 mg/dL, HbA1c 7.6 %, urinary ketone (2+), and pH 7.341. His fasting serum C-peptide level was 0.22 ng/mL, and his anti-GAD antibody was negative, so a diagnosis of fulminant type 1 diabetes mellitus was made. The patient was also found to have low cortisol levels with normal ACTH levels and was diagnosed with secondary hypoadrenocorticism after load tests. In addition, he had FT4 0.16 ng/dL, TSH 111.67 μIU/mL, and hypothyroidism. Intensive insulin therapy, hydrocortisone, and levothyroxine were administered sequentially. This is an extremely rare case in which pembrolizumab caused three endocrine disorders almost simultaneously. We consider this case to be informative regarding the management of endocrinologic immune-related adverse events, and we herein described the findings of this case with a review of the literature.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top